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Abstract
Despite a large amount of in vitro data, the dynamics of airway smooth muscle (ASM) mass increase in the airways of
patients with asthma is not well understood. Here, we present a novel mathematical model that describes qualitatively the
growth dynamics of ASM cells over short and long terms in the normal and inflammatory environments typically observed
in asthma. The degree of ASM accumulation can be explained by an increase in the rate at which ASM cells switch between
non-proliferative and proliferative states, driven by episodic inflammatory events. Our model explores the idea that
remodelling due to ASM hyperplasia increases with the frequency and magnitude of these inflammatory events, relative to
certain sensitivity thresholds. It highlights the importance of inflammation resolution speed by showing that when
resolution is slow, even a series of small exacerbation events can result in significant remodelling, which persists after the
inflammatory episodes. In addition, we demonstrate how the uncertainty in long-term outcome may be quantified and
used to design an optimal low-risk individual anti-proliferative treatment strategy. The model shows that the rate of
clearance of ASM proliferation and recruitment factors after an acute inflammatory event is a potentially important, and
hitherto unrecognised, target for anti-remodelling therapy in asthma. It also suggests new ways of quantifying inflammation
severity that could improve prediction of the extent of ASM accumulation. This ASM growth model should prove useful for
designing new experiments or as a building block of more detailed multi-cellular tissue-level models.
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Introduction
Asthma is a chronic inflammatory disease, characterised by
acute inflammatory events during which antigen exposure triggers
the production or recruitment of inflammatory cells (mast cells, T-
cells, eosinophils, etc.). These cells secrete inflammatory mediators
and growth factors which induce acute inflammation and
bronchoconstriction of an airway wall over the short term (i.e.
minutes to hours) and its remodelling over the long term (i.e. days
to months) [1,2].
Airway smooth muscle (ASM) mass increase is an important
aspect of both airway remodelling and hyper-responsiveness [3,4].
ASM mass accumulation can be triggered by multiple factors,
including inflammation and bronchoconstriction (see Fig. 1).
There is ongoing debate regarding the relative contributions of
ASM cell proliferation, hypertrophy and recruitment (e.g. via
differentiated fibroblasts and myofibroblasts) in asthmatic airways
[5–7]. A large number of inflammatory mediators are associated
with ASM proliferation in vitro, and infiltrating inflammatory cells
are a feature of asthma [8]. However, the precise role of these
factors in ASM mass accumulation in vivo is not well understood
[7]. The many factors involved in airway remodelling, combined
with the difficulties and risks of invasive airway biopsies in patients
with asthma (particularly during exacerbations) and the lack of
consensus on animal models and in vitro systems, have motivated
research on understanding ASM mass increase by non-invasive
means, including mathematical modelling [9,10].
Quantitative data on various aspects of lung function and
airway inflammation can be used to inform mathematical models.
These include [11]: (i) bronchial biopsies, which reveal the amount
of airway wall remodelling and allow one to estimate the
percentage of proliferating and apoptotic ASM cells; (ii) analyses
of inflammatory mediators present in blood and airway sputum
differential cell counts; (iii) exhaled nitric oxide concentration
measurements, and (iv) lung function tests, in particular forced
expiratory volume in one second (FEV1) recordings. The most
direct quantitative information on ASM accumulation, provided
by bronchial biopsies, is very limited due to the invasive nature of
this procedure. Lung function and inflammatory biomarker
measures, however, are more readily performed.
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In this paper, we focus on developing a simple theoretical model
of long-term ASM hyperplasia (proliferation and recruitment) via
inflammatory pathways, which has the potential to integrate the
information from airway biopsies and inflammatory biomarkers.
This model allows possible ASM accumulation scenarios to be
explored and suggests possible new targets for diagnosis and
prevention of ASM remodelling.
Methods
Model formulation and assumptions
We employ a simple model, schematised in Fig. 2(a), in which
we assume ASM cells are either in a proliferative state (which also
accounts for recruitment) or a non-proliferative state [12,13].
These are respectively characterized by time-dependent popula-
tion sizes in an airway wall p(t) and c(t), and the total ASM cell
population is denoted s(t) = p+c. In the following, ‘‘proliferation’’
refers to both cell replication and recruitment, i.e. it is used as a
synonym for hyperplasia.
Switching between the two states is governed by the rates lcp
and lpc. Proliferation of the p-subpopulation is assumed to follow a
logistic law (see S1.1 in Materials S1), with proliferation rate lp,
and maximal population size (‘‘total capacity’’) V. The latter
implicitly includes the effect of spatial constraints in the airway
wall, as well as p-cell apoptosis. For convenience, in the following,
all population sizes are normalised by V, so that the maximum
total cell population size is s = 1. The apoptosis rate of the c-
subpopulation, la, is assumed to be much smaller than lp (la,,
lp) [14]. We also assume that ASM cells do not remain in the
proliferative state for a long time (lpc..lp).
A third variable, the inflammatory status m(t), modulates the
switching rate lcp of ASM cells between the non-proliferative and
proliferative states (Fig. 2(a,b)). We assume that m changes in
response to environmental stimuli of average magnitude a and
average frequency v and decays with a rate ld (the inflammation
clearance rate), as illustrated in Fig. 2(c) (see Materials S1 for
governing equations). The terminology ‘‘inflammatory status’’
refers in this work to all possible downstream triggers of ASM mass
increase, including bronchoconstriction [15,16] (see Fig. 1).
Similarly, ‘‘exacerbation’’, or ‘‘acute inflammatory event’’, refers
to any substantial rapid increase in the inflammatory status
(whether or not this leads to patient hospitalisation).
The way the switching rate lcp varies as a function of m, relative
to the other rate parameters, is depicted in Fig. 2(b). It is
characterised by two thresholds, m1 and m2, such that:
(1) For m,m1 (the ‘‘healthy’’ case), lcp is sufficiently small (la,,
lcp,,lp,,lpc) for the total ASM cell population to remain
approximately stationary (case (1) in Fig. 2(b,d));
(2) For m1#m,m2 (‘‘mild’’ inflammation), lcp is elevated (la,,
lcp<lp,,lpc) such that the ASM cell population increases
on a slow ‘remodelling’ timescale (t<T..1/lp, i.e. weeks to
months; case (2) in Fig. 2(b,d));
(3) For m$m2 (‘‘severe’’ inflammation), lcp is increased further
(la,,lp,,lcp<lpc), allowing ASM cell population to
increase on a fast ‘proliferation’ timescale (t<1/lp, i.e. days
to weeks; case (3) in Fig. 2(b,d)).
Table 1 gives the literature-based values of the model
parameters.
We consider both periodic and irregular timing of exacerbation
events in the simulations. Given the irregular nature of events that
are likely to occur in reality, we seek to explore the impact of this
randomness on ASM remodelling. We run a large number of
simulations (N = 1000), in each of which we allow exacerbation
events to occur randomly according to a Poisson process. The
resulting fold-increase in ASM mass at 300 days is recorded for
each simulation. This may be interpreted as 1000 possible
outcomes in an individual subject given the same average
characteristics (magnitude and mean frequency) from a given
initial state. The outcomes plotted as a histogram then allow
quantification of the likelihood of developing severely or moder-
ately remodelled airways. This is analogous to a weather forecast
in which a number of different possible outcomes are determined
from a given current state.
Solution techniques
We use a combination of analytical techniques (multi-timescale
analysis) and computer simulations (with ode45 MATLAB Runge-
Kutta solver) to characterise the dynamics of the ASM cell
population growth (see S1.2 in Materials S1 for technical details).
Results
Survey of ASM growth scenarios
The fundamental properties of the model are illustrated in
Figure 2(d), where the effect of successive stepwise increases and
decreases of the inflammation status m through the three
inflammation regimes (Fig. 2b) is simulated. Over the considered
time span (about 1 month in each regime), only severe
inflammation (case (3)) leads to substantial growth of the ASM
cell population. In the other two cases, the non-proliferative
phenotype is predominant and population growth is either
negligible (case (1)) or very slow (case (2)). As a consequence,
despite m returning to the initial non-inflammatory value at the
end of the considered period (5 months), the ASM cell population
size has not decreased to its original value. This feature results
from the existence of different timescales in the model and
accounts for the persistence of ASM remodelling in asthma
beyond acute phases of inflammation (in agreement with a recent
chronically-challenged mouse model of asthma [17]). Note that
the theoretical model allows for the existence of a very slow
decrease in ASM mass in the case of prolonged absence of
hyperplastic stimulus (over a timescale of years, thus not apparent
in Fig. 2d). Indeed, our model suggests that there is a dynamic
balance between state-switching, proliferation and apoptosis in a
population of ASM cells: lcp/lpc , la/lp (see S1.2 in Materials
S1). Such a slow decay in ASM mass has been observed recently in
an equine model of asthma (see Discussion and [18]).
Recurrent inflammatory episodes
Figure 3 shows examples of the different proliferation scenarios
that can be encountered under a series of regular inflammatory
events distributed over about one year, depending on the
inflammation magnitude, frequency and resolution rate. When
Figure 1. Possible pathways of chronic ASM mass accumula-
tion in asthma (solid lines indicate the mechanisms included in
the mathematical model).
doi:10.1371/journal.pone.0090162.g001
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the magnitude of inflammatory events is below the ‘‘severe’’
inflammation threshold m2 and the rate of resolution is high, there
is no significant ASM mass increase (Fig. 3a); more severe
inflammatory events, depending on their magnitude, lead to
‘‘moderate’’ (Fig. 3c) or ‘‘severe’’ (Fig. 3d) long-term ASM mass
accumulation. Similarly, changing the frequency of the events
from monthly (Fig. 3b) to semi-monthly (Fig. 3c), for the same
magnitude and resolution rate, results in about two-fold ASM
mass increase.
The outcome of the exacerbation events depends strongly on
whether successive inflammatory events accumulate to increase
the mean inflammatory status (Fig. 3e) or are independent
(Fig. 3(a–d)). In particular, although the frequency and magnitude
of inflammatory events are nearly identical in Figs 3(a) and 3(e),
the ASM mass remains unchanged in Fig. 3(a) while it increases
substantially in Fig. 3(e), due to the slow inflammation resolution.
Figure 4 summarises the possible growth scenarios illustrated in
Fig. 3(a–e). The relative fold-increase in ASM population size
reached at the end of the observation period (300 days) is plotted
as a function of the normalised inflammation resolution rate IR
= ld/lp (vertical axis), and (on the horizontal axis) the normalised
inflammation magnitude a/m1 (Fig. 4a) or frequency v/lp (Fig. 4b).
When the inflammation resolution is very slow (small IR ,,1),
the inflammatory status m accumulates even if individual
exacerbations are mild and infrequent, leading to severe increase
in ASM mass for a wide range of magnitudes and frequencies (red
zones in Fig. 4). Defining the boundaries between ‘‘healthy’’,
‘‘moderate’’ and ‘‘severe’’ outcomes in terms of the isolines for a
Figure 2. A schematic of the model design. (a) Schematic representation of the model with p being the amount of ASM cells in proliferating
state, c the amount of non-proliferative cells and m the inflammatory status; lp is the proliferation rate, la is the apoptosis rate, lcp and lpc are the
switching rates between non-proliferative and proliferative states, ld is the inflammation clearance rate, and f(t) is a time-dependent external
inflammatory stimulus. (b) Dependence of the model parameters on the inflammatory status m (three levels of inflammation are characterised by the
thresholds m1 and m2; see Table 1 for reference values). Rates are plotted on a logarithmic vertical scale. (c) An illustration of the inflammatory status
dynamics induced by a series of environmental stimuli such as shown in (a), illustrating graphically the parameters ld, a, and v. (d) A simulation of the
ASM cell population response (p, blue dash-dotted; c, red dashed; s= p+c, thick black solid) to a stepwise variation in the inflammation status (thin
solid); the arrows show the direction of change in the ASM subpopulations. Although the inflammatory status returns to its initial state at the end of
the simulation, the total ASM cell population has irreversibly increased, showing thereby ‘‘effective’’ hysteresis. Only the time spent in ‘‘severe’’
regime (m.m2) contributes to substantial growth (over weeks); however, the ‘‘moderate’’ regime (m1,m,m2) can also give rise to substantial growth
over a longer timescale (months). Note that the proportion of proliferative cells (blue dash-dotted) is significant only during the ‘‘severe
inflammation’’ regime (3).
doi:10.1371/journal.pone.0090162.g002
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given long-term fold-increase in ASM mass (the two thick solid
lines in Fig. 4(a), corresponding respectively to 2- and 8-fold
increase), we see that the chance of an individual being in the
‘‘moderate’’ ASM growth regime, as either the exacerbation
magnitude or frequency are increased, drops considerably when
the inflammation resolution is slow (IR ,1), indicating the
possibility of a catastrophic shift straight from the ‘‘healthy’’ to the
‘‘severe remodelling’’ scenario when the inflammation resolution is
not fast enough.
For very rapid inflammation resolution (high IR ..1), when
the individual inflammatory episodes are almost independent of
each other, the long-term ASM mass accumulation is determined
solely by the total time spent with inflammatory status above the
‘‘severe’’ inflammation threshold (m$m2). Our analysis (see S1.2 in
Materials S1) shows that this time is linearly proportional to the
exacerbation frequency v, but the dependence on the relative
inflammatory event magnitude a/m2 is nonlinear. Hence, the
isolines of constant ASM growth are expected to obey IR, (v/lp)
log(a/m2) (white dashed lines in Fig. 4; see also S1.2 in Materials
S1). This theoretical prediction agrees well with the computed
growth isolines (thick black lines in Fig. 4) for IR .1. The model
therefore suggests an integral inflammation severity (IS) index
(exposure frequency)|log(exposure magnitude)
(inflammation resolution speed)
(where exposure magnitude is measured relative to the threshold),
which has the potential to be used as a predictor of long-term
ASM remodelling in the case of moderate-to-fast inflammation
resolution. In other words, given the time series of a biomarker of
inflammation for a cohort of patients, the model indicates that the
IS index computed from these series could correlate with the
degree of ASM accumulation in this group.
Individual history effects in ASM growth
For slow recovery from inflammation (IR ,1), substantial ASM
mass growth can occur even if the inflammatory magnitude lies
below the ‘‘severe’’ inflammation threshold (a,m2; see e.g. Fig. 3e),
in contrast to the fast IR case which requires a.m2 for substantial
growth. Therefore, the individual history of inflammatory, pro-
remodelling events can have a very strong impact on the degree of
long-term ASM hyperplasia when successive events can accumu-
late.
Figure 5 illustrates the importance of history in determining the
outcome of a series of inflammatory episodes, when the
inflammation resolution is slow. For given inflammation magni-
tude, frequency and resolution rate, the amount of ASM growth
elicited by an inflammatory event depends crucially on the timing
of the previous inflammatory events. For example, for regular
episodes at a frequency of about once a fortnight (Fig. 5d) and
small inflammation magnitude, the inflammatory status lies well
within the ‘‘moderate inflammation’’ zone after about 40 days,
leading to a ‘‘moderate’’ (less than 3-fold) long-term increase in
ASM mass (Fig. 5a). However, when the events occur irregularly
(Fig. 5(e,f)) with the same average characteristics as in Fig. 5(d), the
individual long-term outcome is much more diverse (Fig. 5(b,c)),
due to the possibility of accumulated inflammatory events or
prolonged periods of remission.
In order to demonstrate the impact of dangerously frequent
exacerbations, Figure 5(g) shows the distribution (histogram) of
N = 1000 possible outcomes in a given individual at the end of an
observation period of 300 days (for a series of random events
exemplified in Fig. 5(e,f)). The distribution is bimodal (i.e. has two
peaks), with one mode being close to the nearly ‘‘healthy’’ state
reached in the absence of randomness (Fig. 5(a,d)), and the other
mode corresponding to severe increase in ASM mass (Fig. 5(c,f)).
Figure 5(h) shows that an increase of only 25% in the
inflammation resolution rate IR can substantially push the mean
of the distribution toward the ‘‘healthy’’ mode. This emphasises
the importance of individual inflammatory history for prognosis
and management of ASM hyperplasia.
We further survey the effect of variability in the timing of acute
inflammatory stimuli in Figure 6, which is the analogue of Fig. 4(a)
for the case of randomly occurring exacerbation events, and is
plotted for a whole range of inflammation resolution rates and
magnitudes. Each point in Fig. 6(a) represents the mean long-term
fold-increase in ASM mass (at the end of 300 days) for given
inflammation characteristics, while each point in Fig. 6(b)
represents the variability of the outcome (quantified as the ratio
of standard deviation to the mean). Some representative distribu-
tions of outcomes are shown in Fig. 6(i–iv).
Figure 6(a) indicates that, at slow resolution rates, the
‘‘moderate remodelling’’ transition zone is larger for random
Table 1. Literature-based and estimated parameter values used in the ASM growth model.
Parameter Value Reference
ASM cell proliferation rate (lp)
* ,1/3 days21 [5,7]
Remodelling time scale (T) ,100 days [2]
Time-scale parameter (e= 1/(lp T)) 0.02
Relative pRc switching rate (lpc/lp) 50 (,e21)
Relative cRp switching rate (lcp/lp) 0.016 (,e) for m,m1,
0.8 (,1) for m1,m,m2,
40 (,e21) for m.m2
Relative ASM apoptosis rate (la/lp) 4610
24 (,e2)
Relative severe inflammatory threshold (m2/m1) 2.5
Relative inflammatory stimulus magnitude (a/m1) 0.1–10
Relative frequency of inflammatory events (v/lp) 0.1–1 (monthly – weekly)
Inflammation resolution rate IR = ld/lp 0.1–10
(* indicates the values estimated from in vitro experiments.)
doi:10.1371/journal.pone.0090162.t001
A Theoretical Model of ASM Accumulation in Asthma
PLOS ONE | www.plosone.org 4 March 2014 | Volume 9 | Issue 3 | e90162
Figure 3. Representative ASM cell population growth dynamics over a period of 300 days, starting from a ‘‘healthy’’ state (c=0.1,
p=0.01), for different values of normalised inflammation magnitude a/m1, frequency v/lp and inflammation resolution rate ld/lp: a/
m1 = {2 (a), 5 (b,c), 8 (d), 1.5 (e)}, v/lp = {0.25 (a,c–e), 0.125 (b)} and ld/lp = {7 (a), 5 (b,c), 2 (d), 0.22 (e)}. (a,b) show no substantial ASM
accumulation, (c,e) show ‘‘moderate’’ and (d) ‘‘severe’’ ASM hyperplasia. The amount of c-cells is depicted by the red line, p-cells (blue) and total
population size s= p+c (thick black). Insets plot the corresponding inflammatory status m (solid black) and the inflammation level thresholds
(horizontal dashed lines).
doi:10.1371/journal.pone.0090162.g003
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inflammatory episodes (Fig. 6a) than for regular episodes (Fig. 4a).
Figure 6(b) shows that the variability of ‘‘healthy’’ and ‘‘severe
remodelling’’ outcomes (blue zone in Fig. 6(b)) is very low;
uncertainty is mainly concentrated in the ‘‘moderate remodelling’’
zone, and rapidly diminishes as resolution speed increases (Fig. 6b).
The high uncertainty region (yellow-to-red, Fig. 6b) is
characterised by a very wide distribution of outcomes, even
though some of these distributions (e.g. Fig. 6(iv)) have relatively
low mean values of long-term ASM growth. These are therefore as
undesirable as high-mean distributions (e.g. Fig. 6(i)) due to a high
risk of ending up with ‘‘severe’’ remodelling in the long term.
Discussion
In this work, we have proposed a simple model of inflammation-
induced ASM hyperplasia, an important aspect of airway
remodelling in asthma. The model assumes that ASM cells can
be in one of two states: ‘proliferative’ (also accounting for the
recruitment and differentiation of fibroblasts and myofibroblasts
by inflammatory mediators [19]) or ‘non-proliferative’. Although
the former is usually associated with a synthetic activity, and the
latter with a contractile activity, we avoided using this additional
terminology here since the synthetic and contractile functions of
ASM cells may not be mutually exclusive [20]. Bidirectional
switching between the two states is allowed (as observed in vitro in
both human ASM cells in culture and in human tracheal smooth
muscle strips [13,21]), and it is assumed that the level of the
inflammatory status m controls the rate of switching between the
two ASM states via the existence of two sensitivity thresholds
(Fig. 2b). With the aid of mathematical techniques (see Materials
S1), we have shown that this leads to the existence of three
corresponding ASM growth regimes (Fig. 2d) and three qualita-
tively different remodelling outcomes (Figs 4 and 6), matching the
classification commonly used in clinical practice [6,22].
The existence of different timescales in the model accounts for
several important features of asthma:
i. the persistence of airway remodelling despite the resolution of
acute inflammation [1,17], and the correlation of ASM mass
with asthma severity rather than with asthma duration [23];
ii. the presence of airway remodelling and abnormal lung
function very early in the history of asthma [24];
iii. the very slow decline (of the order of years) in ASM mass in
the continued absence of hyperplastic stimuli [18].
Feature (i) can be directly related to Fig. 2(d); feature (ii) can be
explained by m having crossed the severe inflammation threshold,
and remained above it a substantial amount of time, early in the
disease history; feature (iii) is consistent with the non-negligible role
played by apoptosis when the inflammatory status is kept in the
healthy range (Fig. 2b) for a sufficiently long time (longer than that
considered in Fig. 2(d); see also S1.2 in Materials S1).
Cumulative effects of individual inflammatory history at
slow resolution rate
Assuming that inflammatory events are characterised by
transient increases in the inflammatory status m (Fig. 2c), our
model predicts that long-term ASM growth is essentially
controlled by three parameters: the inflammation resolution speed
(IR), the inflammation magnitude (relative to the two sensitivity
thresholds m1 and m2) and the frequency of inflammatory episodes.
The severity and frequency of the inflammatory episodes could be
targeted to ensure that an asthmatic individual does not fall into
the dangerous ‘‘severe remodelling’’ zone (red in Fig. 4). However,
our model indicates that faster inflammation resolution could offer
a better protection against severe ASM remodelling by increasing
the probability of ‘‘healthy state’’ or ‘‘moderate’’ growth (see
Figs 4a and 6a).
In addition, irregularity of the occurrence of inflammatory
episodes, together with the existence of sensitivity thresholds, lead
to a large variability of growth scenarios (see ‘‘moderate
remodelling’’ region in Figs 5(b,c) and 6). Thus, one should take
into account not only the expected outcome but also the degree of
Figure 4. Survey of ASM growth scenarios, showing fold-increase in ASM population size after 300 days (colour scale) as a function
of the inflammation resolution rate IR = ld/lp and (a) inflammation magnitude a/m1 (for fixed frequency v/lp =0.25) or (b)
inflammation frequency v/lp (for fixed magnitude a/m1 =5). White dots indicate the growth regimes shown in Fig. 2. Solid black lines are the
computed isolines of the 2- and 8-fold ASM growth, which agree with the theoretically predicted dependence ld , v log a/m2 (dashed white lines;
see Materials S1).
doi:10.1371/journal.pone.0090162.g004
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uncertainty when deciding on the optimal low-risk treatment
strategy (see arrows in Fig. 6a). That means it would be desirable
to avoid high outcome variability (Fig. 6b) when navigating
towards the ‘‘healthy’’ state by varying the inflammation
resolution speed, magnitude or frequency. (Note that another
possibility would be to modify the landscape of outcomes itself by
elevating the inflammation sensitivity threshold m2, thereby
‘‘moving the mountain rather than the man’’). These results
emphasise the importance of individual inflammatory history for
prognosis and management of ASM hyperplasia in individuals
where slow resolution of inflammation is suspected.
A recent study of a horse model of asthma [18] supports these
results by comparing the effect of inflammation resolution speed
(modulated by corticosteroids) and the role of frequency and
severity of environmental stimuli (by avoidance of antigen
exposure). Leclere and colleagues have shown that treatment with
corticosteroids gives more rapid (compared to pure antigen
avoidance) effects on lung function and ASM remodelling [18],
which agrees with our model’s prediction of the higher importance
of rapid inflammation resolution over stimulus magnitude (see
Fig. 6a). This prediction is also supported by the acceleration of
ASM mass decline by corticosteroids observed in human
peripheral airways after a 6-week treatment [25]. Indeed, the
ASM cell population can decrease (very slowly) only when m is
below the mild inflammation threshold (Fig. 2b). The larger the
inflammation resolution speed, the sooner this long-term recovery
regime can be reached.
Long-term ASM mass accumulation at moderate-to-fast
resolution rate
Faster resolution of inflammation decouples individual pro-
inflammatory events and thus diminishes the effect of inflamma-
Figure 5. The role of individual inflammation history in the case of slow inflammation resolution (IR ,,1). (a–c) ASM population size
dynamics (c-cells, red; p-cells, blue; total population s, black) and (d–f) the corresponding inflammatory status evolution (m, solid black; inflammatory
thresholds m1 and m2, dashed), characterized by the same inflammation resolution rate, magnitude and average stimulus frequency (ld/lp = 0.08, a/
m1 = 0.5, v/lp = 0.25). (d) Regular series of inflammatory events; (e–f) two realisations of a series of inflammatory events at random times for the same
mean frequency (about once a fortnight) as in (d). (g) Distribution of fold-increase in ASM mass after 300 days for a random sequence of inflammatory
events with the same characteristics as in panels (b, c); arrows indicate the fold-increase corresponding to (a–c). (h) The distribution of outcomes with
an increase of 25% in the inflammation resolution rate (ld/lp = 0.1). (The outcome histograms (g,h) are computed for N=1000 instances).
doi:10.1371/journal.pone.0090162.g005
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tion history in ASM growth. Although this seems to provide
greater control over ASM population growth, a mild-to-moderate
accumulation of ASM mass over the long term can still occur,
provided the magnitude of the exacerbation is above the second
threshold m2. The model predicts that long-term ASM mass
accumulation is proportional to exacerbation frequency but
depends less strongly on exacerbation magnitude (see the growth
isolines in Fig. 4). The frequency of the pro-inflammatory events
could therefore be considered a secondary target, after ensuring
rapid resolution of inflammation. The importance of antigen
exposure frequency in the degree of airway remodelling has been
also confirmed in animal models [26].
Given that resolution of exacerbations can be affected by
current therapies [27] and that clinical factors associated with
frequent exacerbations are well recognised [28], mechanism-
derived links between these factors and exacerbations could be
targeted in future studies to prevent airway remodelling.
Model limitations and further development
While accounting for the key features of ASM growth, the
proposed model neglects many potentially important factors, such
as the detailed pathways governing ASM hyperplasia. However,
the kinetic parameters for these pathways remain largely
unknown. The generality of our model is also a strength, in that
its predictions do not depend on the precise nature of the signalling
events (leading to the increase in the ‘‘inflammatory status’’) but
only on their dynamical features (magnitude, frequency, resolution
speed). In particular, the model is compatible with bronchocon-
striction acting as a trigger of airway remodelling [15,16].
We have not included mechanical interaction of the cells
between each other and with the extracellular matrix that could
affect the growth and apoptosis rates as well as the total capacity V
of an airway wall. Our model additionally neglects the spatially
heterogeneous and anisotropic growth observed in micrographs
and cell hypertrophy. Therefore, the predictions of this ASM
growth model are qualitative rather than quantitative.
Figure 6. Survey of stochastic ASM growth scenarios in the region of low-to-moderate inflammation resolution rate. (a) Mean fold-
increase in the ASM population size at 300 days (colour scale) as a function of inflammation resolution rate IR =ld/lp and inflammation magnitude a/
m1 (cf. Fig. 3a). (b) Corresponding uncertainty (colours) quantified as the ratio of SD to the mean; white lines indicate the uncertainty isolines. (Solid
black lines in (a,b) show 2- and 8-fold increase in mean; computed for a sample size of N=500 random realisations). The parameter dependence of
outcome distributions (N=5000) are illustrated in (i–iv), indicated by white dots in (a). (Note the variation in vertical scales between panels (i, iii) and
(ii, iv)). The quickest transition from (i) to (iii) crosses the high uncertainty region ((iv), red in panel (b)), while a trajectory that bypasses it (white line in
(a)) protects against ‘‘severe’’ remodelling outcomes.
doi:10.1371/journal.pone.0090162.g006
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Extra care should also be taken when interpreting the results of
the model in terms of its impact on respiratory lung function.
Relative increase in the lumen-narrowing contractile force of an
airway wall due to a larger ASM mass could be balanced by a
simultaneous increase in the wall stiffness, which may have a
constriction-limiting effect [29]. Future models should therefore
focus on coupling the mechanics of an airway wall and the ASM
population dynamics [29–31].
Further experiments to test the model prediction of the role of
inflammation resolution rate in co-cultures of inflammatory and
ASM cells or in animal models (such as the studies of Garn and co-
workers [17,32]) would be desirable. It would also be of interest to
use the model results (in particular, the inflammation severity
index) for a detailed statistical analysis of inflammatory status from
a time series of inflammatory biomarkers (such as eosinophil
counts in sputum or exhaled nitric oxide concentration) and their
relation to ASM mass in bronchial biopsies. To our knowledge
such longitudinal studies have not yet been performed, due to the
difficulties in carrying out repetitive airway biopsies in humans.
Conclusions
We have developed and analysed a theoretical model of ASM
mass accumulation driven by a series of exacerbation events. Our
model highlights the importance of the resolution speed of
inflammation in long-term management of asthma. It exposes
the possibility of false security of strict antigen avoidance or
reduced sensitivity to inflammatory stimuli. A few accidental
exposures or acute exacerbations at impaired resolution can lead
to the accumulation of inflammatory status and hence relatively
rapid ASM remodelling.
A more robust anti-remodelling strategy could lie in ensuring
the rapid clearance of growth or recruitment factors during the
post-exacerbation period, thereby protecting against dangerous
build-up of these factors, latent ASM mass increase and reducing
the risk of severe remodelling.
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